Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

Iron, an indispensable element for life, is involved in all kinds of important physiological
activities. Iron promotes cell growth and proliferation, but it also causes oxidative stress …

Background Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-
SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute …

Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell …

Background Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs)
might improve clinical outcome of patients with B cell malignancies. This is the first report on …

The interaction of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)
blasts with the bone marrow microenvironment regulates self-renewal, growth signaling, as …

T cell immunoglobulin and mucin domain 3 (TIM-3) expression on malignant cells has been
reported in some leukemias. In myelodysplastic syndrome (MDS), increased TIM-3 …

Bispecific antibodies (BsAbs) are designed to recognize and bind to two different antigens or
epitopes. In the last few decades, BsAbs have been developed within the context of cancer …

B-and T-cell acute lymphoblastic leukemia (B/T-ALL) may be refractory or recur after therapy
by suppressing host anticancer immune surveillance mediated specifically by natural killer …

Acute lymphoblastic leukemia (ALL) is a malignancy of lymphoid progenitor cells occurring
at an annual incidence rate of approximately 1.1–2.1 per 100,000 person-years globally …